Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 12/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885324 | 1.00 | ADK (0.62) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL2143269 | 1.00 | ADK (0.62) | ADKDOT1LNPC1GALR3S1PR4 | |
| SCHEMBL6570558 | 0.86 | SLC29A1 (0.52) | ADKDOT1LSLC28A1SLC28A2SLC29A1 | |
| Tubercidin SCHEMBL1739818 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL23982115 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL23982350 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL6063615 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL20938187 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL20418952 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 | |
| Tubercidin SCHEMBL23351430 | 0.83 | ADK (0.82) | ADKDOT1LDPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2107909-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX Pharmaceuticals, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-7081449-B2 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | VALEANT RESEARCH & DEVELOPMENT (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1303282-A4 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | RIBAPHARM INC (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | MDRNA RESEARCH, INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1303282-A1 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | Ribapharm, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002003997-A1 | PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES | RIBAPHARM INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144502-A1 | Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides | DPYD, TYMP, PNPO | ADK 384/4885DOT1L 4144/4885NPC1 3327/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | ADK 226/4885DOT1L 992/4885NPC1 585/4885 |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | NRAS, BRAF, MAP3K2 | ADK 1466/4885DOT1L 2921/4885NPC1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.